CGEN vs. GNFT, ADVM, CLLS, ELEV, VCXB, XFOR, FENC, KOD, CRDF, and IPSC
Should you be buying Compugen stock or one of its competitors? The main competitors of Compugen include Genfit (GNFT), Adverum Biotechnologies (ADVM), Cellectis (CLLS), Elevation Oncology (ELEV), 10X Capital Venture Acquisition Corp. III (VCXB), X4 Pharmaceuticals (XFOR), Fennec Pharmaceuticals (FENC), Kodiak Sciences (KOD), Cardiff Oncology (CRDF), and Century Therapeutics (IPSC). These companies are all part of the "biological products, except diagnostic" industry.
Genfit (NASDAQ:GNFT) and Compugen (NASDAQ:CGEN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership, community ranking and dividends.
Genfit has a beta of 1.06, indicating that its share price is 6% more volatile than the S&P 500. Comparatively, Compugen has a beta of 2.72, indicating that its share price is 172% more volatile than the S&P 500.
Compugen's return on equity of 0.00% beat Genfit's return on equity.
2.2% of Genfit shares are held by institutional investors. Comparatively, 12.2% of Compugen shares are held by institutional investors. 4.2% of Genfit shares are held by company insiders. Comparatively, 9.5% of Compugen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Compugen received 239 more outperform votes than Genfit when rated by MarketBeat users. However, 68.09% of users gave Genfit an outperform vote while only 64.33% of users gave Compugen an outperform vote.
Compugen has lower revenue, but higher earnings than Genfit.
In the previous week, Compugen had 1 more articles in the media than Genfit. MarketBeat recorded 8 mentions for Compugen and 7 mentions for Genfit. Compugen's average media sentiment score of 0.50 beat Genfit's score of 0.25 indicating that Genfit is being referred to more favorably in the media.
Genfit currently has a consensus price target of $11.00, indicating a potential upside of 172.28%. Compugen has a consensus price target of $4.00, indicating a potential upside of 103.05%. Given Compugen's higher probable upside, analysts clearly believe Genfit is more favorable than Compugen.
Summary
Genfit and Compugen tied by winning 7 of the 14 factors compared between the two stocks.
Get Compugen News Delivered to You Automatically
Sign up to receive the latest news and ratings for CGEN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Compugen Competitors List
Related Companies and Tools
